EDIL3 Diagnostic Kit for Early APOE4 Synaptic Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for diagnosing and treating Alzheimer's disease are inadequate, particularly in identifying early synaptic dysfunction associated with APOE4 alleles, which are a significant genetic risk factor for the disease.

Innovation Solution

A kit and pharmaceutical composition utilizing nucleic acid primers, probes, and antibodies targeting EDIL3, a protein highly expressed by astrocytes with the APOE4 allele, to detect and inhibit EDIL3, thereby diagnosing and treating Alzheimer's disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current diagnostic methods are used for Alzheimer's disease, then general dementia detection is possible, but early synaptic dysfunction associated with APOE4 alleles cannot be identified

Engineering Contradiction:

Improvedetection accuracyVSAvoidearly synaptic dysfunction detection

Core Design Contradiction:

Measurement precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The diagnostic approach is segmented into multiple components: detecting APOE4 genotype status, quantifying EDIL3 protein levels, and assessing neuronal morphological abnormalities. This segmentation allows specific early synaptic dysfunction markers to be identified separately from general dementia symptoms, improving detection precision for early-stage APOE4-related pathology.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The kit enables preliminary detection of APOE4-associated synaptic dysfunction before full-blown Alzheimer's disease manifests. By measuring EDIL3 levels and neuronal morphology in advance, the system allows early intervention strategies to be implemented before irreversible neurodegeneration occurs.

Inventive Principle:

Principle #10Preliminary action

2Loss of information

If APOE4 allele carriers are identified, then genetic risk assessment is improved, but specific early synaptic dysfunction markers are still lacking

Engineering Contradiction:

Improvegenetic risk informationVSAvoidsynaptic dysfunction measurement

Core Design Contradiction:

Loss of informationVSMeasurement precision

Solution Approach 1:

The diagnostic system merges genetic information (APOE4 genotype detection) with biochemical markers (EDIL3 protein quantification) and morphological assessment (neuronal spine density evaluation). This combination provides a comprehensive risk assessment that links genetic predisposition with actual synaptic dysfunction, eliminating the information gap between genetic risk and physiological impact.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The system provides feedback by correlating APOE4 genotype status with EDIL3 protein levels and neuronal morphology. This feedback loop allows clinicians to assess not only genetic risk but also the actual functional impact on synapses, enabling more precise diagnostic stratification of APOE4 carriers.

Inventive Principle:

Principle #23Feedback

3Reliability

If EDIL3 is present in cell culture medium, then astrocyte function is maintained, but neuronal morphological abnormalities occur

Engineering Contradiction:

Improveastrocyte functionVSAvoidneuronal morphological abnormality

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention converts the harmful effect of EDIL3 on neurons into a beneficial diagnostic tool. By quantifying EDIL3 levels in patient samples, the system uses the presence of this harmful protein as a marker for early Alzheimer's disease detection in APOE4 carriers, transforming a pathological factor into a diagnostic advantage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

EDIL3 acts as an intermediary molecule that mediates the harmful interaction between APOE4-expressing astrocytes and neurons. The diagnostic kit targets this intermediary by measuring EDIL3 levels, thereby detecting the pathological communication between glial and neuronal cells that characterizes early APOE4-related Alzheimer's disease.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The kit and composition enable accurate diagnosis and potential treatment by quantifying EDIL3 levels, identifying neuronal morphological abnormalities, and inhibiting EDIL3 function to mitigate disease progression.

Implementation Method 1

a nucleic acid primer or nucleic acid probe that detects an mRNA encoding EDIL3

Methodology Applied

Scientific EffectNucleic acid hybridization:

Implementation Method 2

an anti-EDIL3 antibody or an EDIL3 binding fragment

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS20260043791A1Kit for diagnosing alzheimer's disease and pharmaceutical composition for treating alzheimer's disease

Publication Date: 2026.02.12 EISAI R&D MANAGEMENT CO LTD

AI summary

A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.